secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001628280-24-048593
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics appoints Steve Hoerter, former Deciphera CEO, to board of directors
--------------------------------------------------------------------------------

- Steven L. Hoerter appointed as Class II director effective November 19, 2024; serves until 2025 annual meeting.
- Hoerter has over 30 years of oncology leadership; was CEO of Deciphera (acquired by ONO for $2.4B).
- Granted 65,000 stock options under 2020 Plan; vests 1/3 on first anniversary, remainder quarterly over 2 years.
- Board determined Hoerter independent per Nasdaq standards; brings commercialization expertise to guide pipeline.
- Hoerter also serves on ORIC Pharmaceuticals board; previously led QINLOCK and TIBSOVO launches.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024048593/0001628280-24-048593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024048593/cccc-20241120.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-048593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer